Welcome to our dedicated page for Ocugen SEC filings (Ticker: OCGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ocugen, Inc. (NASDAQ: OCGN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central for understanding Ocugen’s development plans in gene therapies for blindness diseases, its financial condition, and key corporate actions.
Ocugen uses Form 8‑K current reports to announce material events, including exclusive licensing agreements, registered direct offerings of common stock and warrants, litigation developments, and Nasdaq listing compliance updates. For example, recent 8‑K filings describe an exclusive license agreement with Kwangdong Pharmaceutical Co., Ltd. for OCU400 in the Republic of Korea, a securities purchase agreement for a registered direct offering, and court decisions related to a securities class action lawsuit.
Periodic reports such as Form 10‑Q and Form 10‑K (when available) provide more comprehensive information on Ocugen’s financial results, operating expenses, and risk factors. In a recent earnings-related press release furnished on Form 8‑K, the company detailed revenue from collaborative arrangements, research and development expenses, general and administrative expenses, and net loss figures, along with commentary on cash runway and financing plans.
Investors can also review filings that discuss executive compensation and equity awards, such as performance restricted stock units granted to senior leadership, and agreements related to licensing, supply, and regional commercialization of products like OCU400. These filings help clarify how management is incentivized and how Ocugen structures partnerships around its modifier gene therapy platform.
On Stock Titan, Ocugen’s SEC filings are updated in near real time from the EDGAR system. AI-powered tools summarize lengthy documents, highlight key sections on clinical programs, licensing terms, capital raises, and governance matters, and make it easier to locate items such as quarterly results, material agreements, and other disclosures relevant to OCGN stock.
Ocugen has announced a significant merger agreement between its wholly-owned subsidiary OrthoCellix (holding Neocart product assets) and Carisma Therapeutics. The merger will result in OrthoCellix becoming a wholly-owned subsidiary of Carisma, with the following key terms:
- Ownership structure: Ocugen and concurrent investors will own approximately 90% of the combined company, while pre-merger Carisma stockholders will own 10%
- Valuation: OrthoCellix valued at $135 million (subject to adjustment), Carisma at $15 million
- Concurrent Investment: Minimum $25 million investment planned, with Ocugen committing at least $5 million
- Board composition: 6 members total - 5 designated by OrthoCellix, 1 by Carisma
The deal includes termination fees ($500,000 from Carisma or $750,000 from OrthoCellix under specific conditions), lock-up agreements, and CVRs for pre-merger Carisma stockholders. The merger is subject to stockholder approval, Nasdaq listing requirements, and other customary closing conditions.